Author:
Maunz Andreas,Barras Laura,Kawczynski Michael G.,Dai Jian,Lee Aaron Y.,Spaide Richard F.,Sahni Jayashree,Ferrara Daniela
Reference24 articles.
1. Ten years of anti-vascular endothelial growth factor therapy;Ferrara;Nat Rev Drug Discov,2016
2. Pipeline therapies for neovascular age related macular degeneration;Arepalli;Int J Retina Vitreous,2021
3. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials;Heier;Lancet,2022
4. Archway randomized phase 3 trial of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration;Holekamp;Ophthalmology,2022
5. Artificial intelligence-based predictions in neovascular age-related macular degeneration;Ferrara;Curr Opin Ophthalmol,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献